Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Mahal

Showing results (161-170 of 210) with videos related to

Pageof 21
Sort By:
Clinical Genitourinary Cancer|May 28, 2014
Racial disparities in prostate cancer-specific mortality in men with low-risk prostate cancerBrandon A Mahal, Ayal A Aizer, David R Ziehr, et al.
Prostate Cancer and Prostatic Diseases|July 2, 2014
The association between insurance status and prostate cancer outcomes: implications for the Affordable Care ActB A Mahal, A A Aizer, D R Ziehr, et al.
Cancer|January 7, 2020
Genomic and clinical characterization of stromal infiltration markers in prostate cancerBrandon A Mahal, Mohammed Alshalalfa, Shuang G Zhao, et al.
Nature Structural & Molecular Biology|November 7, 2022
Endocrine resistance and breast cancer plasticity are controlled by CoRESTLiliana Garcia-Martinez, Andrew M Adams, Ho Lam Chan, et al.
Cancer|December 13, 2017
Travel distance and stereotactic body radiotherapy for localized prostate cancerBrandon A Mahal, Yu-Wei Chen, Roshan V Sethi, et al.
The American Journal of Medicine|February 4, 2015
Who bears the greatest burden of aggressive treatment of indolent prostate cancer?Brandon A Mahal, Matthew R Cooperberg, Ayal A Aizer, et al.
Brachytherapy|June 2, 2014
Use of a rectal spacer with low-dose-rate brachytherapy for treatment of prostate cancer in previously irradiated patients: Initial experience and short-term resultsBrandon A Mahal, David R Ziehr, Andrew S Hyatt, et al.
Cancer|July 20, 2016
National sociodemographic disparities in the treatment of high-risk prostate cancer: Do academic cancer centers perform better than community cancer centers?Brandon A Mahal, Yu-Wei Chen, Vinayak Muralidhar, et al.
Nature Reviews. Urology|October 18, 2024
Racial disparities in prostate cancer in the UK and the USA: similarities, differences and steps forwardsEdward Christopher Dee, Rebecca Todd, Kenrick Ng, et al.
International Journal of Radiation Oncology, Biology, Physics|May 3, 2017
National Trends and Predictors of Androgen Deprivation Therapy Use in Low-Risk Prostate CancerDavid D Yang, Vinayak Muralidhar, Brandon A Mahal, et al.
Pageof 21

Showing results (161-170 of 210) with videos related to

Sort By:
Pageof 21
Clinical Genitourinary Cancer|May 28, 2014
Racial disparities in prostate cancer-specific mortality in men with low-risk prostate cancerBrandon A Mahal, Ayal A Aizer, David R Ziehr, et al.
Prostate Cancer and Prostatic Diseases|July 2, 2014
The association between insurance status and prostate cancer outcomes: implications for the Affordable Care ActB A Mahal, A A Aizer, D R Ziehr, et al.
Cancer|January 7, 2020
Genomic and clinical characterization of stromal infiltration markers in prostate cancerBrandon A Mahal, Mohammed Alshalalfa, Shuang G Zhao, et al.
Nature Structural & Molecular Biology|November 7, 2022
Endocrine resistance and breast cancer plasticity are controlled by CoRESTLiliana Garcia-Martinez, Andrew M Adams, Ho Lam Chan, et al.
Cancer|December 13, 2017
Travel distance and stereotactic body radiotherapy for localized prostate cancerBrandon A Mahal, Yu-Wei Chen, Roshan V Sethi, et al.
The American Journal of Medicine|February 4, 2015
Who bears the greatest burden of aggressive treatment of indolent prostate cancer?Brandon A Mahal, Matthew R Cooperberg, Ayal A Aizer, et al.
Brachytherapy|June 2, 2014
Use of a rectal spacer with low-dose-rate brachytherapy for treatment of prostate cancer in previously irradiated patients: Initial experience and short-term resultsBrandon A Mahal, David R Ziehr, Andrew S Hyatt, et al.
Cancer|July 20, 2016
National sociodemographic disparities in the treatment of high-risk prostate cancer: Do academic cancer centers perform better than community cancer centers?Brandon A Mahal, Yu-Wei Chen, Vinayak Muralidhar, et al.
Nature Reviews. Urology|October 18, 2024
Racial disparities in prostate cancer in the UK and the USA: similarities, differences and steps forwardsEdward Christopher Dee, Rebecca Todd, Kenrick Ng, et al.
International Journal of Radiation Oncology, Biology, Physics|May 3, 2017
National Trends and Predictors of Androgen Deprivation Therapy Use in Low-Risk Prostate CancerDavid D Yang, Vinayak Muralidhar, Brandon A Mahal, et al.
Pageof 21